Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. In the original version, one of the authors of the above article was listed incorrectly as Paolo Casali rather than Silvia Stacchiotti. This has now been corrected.